BioSpace News Archive

-- Drug being evaluated for improved functional outcomes and survival rates for patients resuscitated after a cardiac arrest --

Bad Habits Tattoos in Fort Lauderdale, Florida is now a full-service tattoo studio thanks to their new addition of the Astanza Duality laser.

Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the U.S. Food and Drug Administration (FDA) has extended the review period for its new drug application (NDA) for solriamfetol as a treatment to improve wakefulness and reduce excessive daytime sleepiness in adult patients with narcolepsy or obstructive sleep apnea (OSA).

Medivir AB today announced that the first patient in the phase ll part of the BPT-201 study of birinapant in combination with Keytruda® (pembrolizumab) has been dosed.

CStone Pharmaceuticals (“CStone”) today announced the successful enrollment and dosing of the first three patients in a Phase I clinical trial in the United States for CS1001, China’s first fully human and full-length anti-PD-L1 monoclonal antibody.

Donation aimed at raising awareness of older adult hunger and food insecurity in Ohio

Rapid high-magnitude and durable treatment responses were seen at all dose levels tested in a heavily pre-treated Phase 1 patient population.

Warfighter Hemp proposed the VA Medicinal Hemp Research Act of 2018, to authorize the Department of Veterans Affairs to advance scientific and medical research into the safety and efficacy of medicinal hemp usage by veterans with diagnoses such as post-traumatic stress disorder and chronic pain.

FSD Pharma Inc. in response to Therapix Biosciences’ termination of the company’s binding letter of intent to be acquired by FSD Pharma, Dr. Raza Bokhari, Executive Co-Chairman of the Board of FSD Pharma, released the following statement

eHealth, Inc. announced the appointment of Andrea Brimmer as an independent director to eHealth’s Board of Directors